Case Serieslow evidence
An iPSC-derived neural progenitor cell therapy for subacute spinal cord injury: a phase 1 trial with long-term follow-up.
Nature medicine·July 21, 2026·PMID 42481854
Why it mattersComplete cervical spinal cord injury currently lacks restorative therapies, leaving patients with permanent severe disability. This trial provides the first human evidence that iPSC-based neural cell transplantation is feasible and safe under short-term immunosuppression, with motor improvements that surpass natural history, opening a potential avenue for functional recovery in a condition with high unmet need.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled